Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2010-12-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT00321815
- Locations
- 🇺🇸
Pfizer Investigational Site, Dalls, Texas, United States
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT00307736
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 11
- Registration Number
- NCT00301418
- Locations
- 🇺🇸
Lenox Hill Brain Tumor Center, New York, New York, United States
IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 842
- Registration Number
- NCT00300586
- Locations
- 🇫🇷
Maurice PEROL, Lyon, France
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2011-07-15
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 21
- Registration Number
- NCT00287222
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Kansas University Medical Center, Kansas City, Kansas, United States
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-01-18
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Nathan Pennell, MD, PhD
- Target Recruit Count
- 32
- Registration Number
- NCT00278148
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2018-10-24
- Target Recruit Count
- 249
- Registration Number
- NCT00276744
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone
- Conditions
- Interventions
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 162
- Registration Number
- NCT00265317
- Locations
- 🇪🇸
Pfizer Investigational Site, Santander, Cantabria, Spain
Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7Recurrent Lung Non-Small Cell CarcinomaStage IA Lung Non-Small Cell Carcinoma AJCC v7Stage IIA Lung Non-Small Cell Carcinoma AJCC v7Stage IIB Lung Non-Small Cell Carcinoma AJCC v7Stage IIIA Lung Non-Small Cell Cancer AJCC v7Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00254384
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
- Conditions
- Interventions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 23
- Registration Number
- NCT00251589
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.